New Technology Identifies Hodgkin’s Patients Unlikely to Respond to Chemotherapy, Company Says
News
A new technology called Telo-HL, developed by 3D Signatures (3DS), is able to distinguish Hodgkin’s lymphoma patients who respond to standard chemotherapy from those who do not, the company announced. An independent analysis ... Read more